Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of inducement awards to brian robinson, its new senior vice president, global medical affairs. the compensation committee of atara's board of directors granted mr. robinson 73,449 restricted stock units of atara'
ATRA Ratings Summary
ATRA Quant Ranking